ESLA.US Estrella Immunopharma Inc.

Healthcare Biotechnology USA Stocks
0.5140 USD
Close of Nov 13, 2026
0.2400 2.33
Market cap
USD 22.4M
P/E
-
P/B
4.13x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ESLA.US undervalued?

Graham number

The Graham number of Estrella Immunopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Estrella Immunopharma Inc. fundamental analysis

No fundamental analysis for Estrella Immunopharma Inc. yet.

Estrella Immunopharma Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Estrella Immunopharma Inc.

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lu…

Full company profile